UCB's Pivot to Transformative Platforms: Peak Sales Raised to EUR 7B Amid a Flurry of M&A
Strong H1 execution and a redefined growth strategy — cell therapy and T-cell engagers — extend visibility beyond 2037.
UCB.BR · Earnings Call · 2026-07-30
Growth Engine Recalibrated: BIMZELX Peak Sales Raised to EUR 7B
The first half of 2026 delivered more than just strong numbers; it forcibly recalibrated the ceiling on UCB's largest asset. “Our revised peak sales potential of at least EUR 7 billion, like JC mentioned earlier today for BIMZELX” — Fiona du Monceau, Executive (likely Head of Commercial or similar) · 2026-07-30 – up from the "at least EUR 4 billion" guidance set less than two years ago. The upgrade is rooted in execution: BIMZELX net sales reached EUR 1.5 billion in H1, more than double the prior year, with the five growth drivers now contributing over half of total revenue at a 28% constant-rate growth clip. The BE BOLD trial – a head-to-head against SKYRIZI in psoriatic arthritis – produced the first-ever superiority result on ACR50, giving the franchise a durable evidence advantage.Pivoting to Transformative Modalities: Cell Therapy and T-cell Engagers
The more consequential shift isn't the numbers, but the strategic posture. UCB has historically been a small-molecule and antibody house. That changed decisively in H1 with four acquisitions/in-licensings, most notably Neurona (allogeneic GABA interneuron cell therapy for epilepsy) and Candid Therapeutics (BCMA T-cell engager). Emmanuel Caeymaex framed the logic: “we've been observing the field of CAR-Ts for quite a few years and have decided to invest in T-cell engagers, first with the licensing of ATG-201 and second, with the acquisition of Candid Therapeutics because those medicines really promise a transformative potential, meaning drug-free remission for, potentially, quite a long period of time in a manner that is scalable.” — Emmanuel Caeymaex, Executive (likely Head of R&D or similar) · 2026-07-30 This is a clear escalation of ambition from "deeper clinical response" to "drug-free remission and potentially even cure." The counterpoint is that the company has been signaling BD interest for quarters but has now put real capital behind it. In the February 2026 call, Jean-Christophe Tellier had said: “We are now a little bit more intentional on that with the objective to strengthen our capabilities, thinking about the long-term growth and be careful about not disrupting the execution of the launches.” — Jean-Christophe Tellier, Unknown · 2026-02-28 The acquisitions are still early-stage, but they represent a diversification of risk away from a BIMZELX-centric future. The cell therapy play, in particular, leverages UCB's existing leadership in epilepsy – a therapeutic area that had been growing via FINTEPLA but now gains a potential disease-modifying option.Margin Expansion and Guidance Upgrade: Phasing or New Normal?
The financial performance was equally striking. Adjusted EBITDA rose 68% (79% CER) to EUR 1.7 billion, with margin reaching 40.7% in H1. CFO Sandrine Dufour was careful to frame this as partly phasing: “The strong H1 margin should be read as a phasing related rather than a new run rate.” — Sandrine Dufour, Executive (likely CFO or Head of Finance) · 2026-07-30 Yet guidance was upgraded to mid-teens to low-20s CER EBITDA growth for the full year, implying continued strong leverage even as R&D and marketing costs ramp in H2. The company also confirmed comfort with consensus for BIMZELX 2026 (around EUR 3.5 billion), despite the pricing pressure expected from the new first-line PBM contract effective June 1. That trade-off – near-term net price erosion for long-term volume and share – is a deliberate bet the call acknowledged. The call echoes remarks from last year, when the CFO noted that “the long-term ambition is to achieve the comparable profitability levels” — Sandrine Dufour, Chief Financial Officer · 2025-08-01 – illustrating that the current margin trajectory, while above historical norms, is part of a longer-term plan rather than a one-off spike.Strategic Flexibility and a De-risked Future
Perhaps the most unique element of UCB's story is the absence of meaningful loss of exclusivity until well into the next decade. As Jean-Christophe Tellier put it:That tailwind underpins the confidence to reinvest aggressively today, both organically (bepranemab advancing to Phase II despite a missed primary endpoint, based on a strong low-TAU signal) and inorganically. The contrast with the prior quarter's caution is stark. During the February 2026 call, analysts were still asking about "BD appetite" as a hypothetical; now it is a reality with four deals closed. The pivot to licensing of T-cell engagers alongside the cell therapy acquisition is not just a diversification play – it's a statement that UCB intends to remain a leader in severe chronic disease beyond the current portfolio's patent cliff. Still, the market will be watching two things: whether the BIMZELX pricing reset in H2 2026 creates an even deeper trough than guided, and whether the margin step-down is truly phasing or the start of a higher-spend regime. The company has provided a clear rationale – the pricing effect of expanded access and the phasing of R&D costs – but the proof will be in the second-half numbers. For now, the narrative has shifted from "strong execution on a growth portfolio" to "a multi-modal growth platform with 10+ years of runway." That is a fundamentally different, and more interesting, story.The first product that will lose exclusivity in the near future is FINTEPLA in 2033. And the last one will be BIMZELX in 2037. So we still have, ahead of us, 10 years of growth with BIMZELX.